Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) (“Acurx” or the “Company”), a late-stage biopharmaceutical company developing a new class of small molecule antibiotics for difficult-to-treat bacterial infections, today announced that a new patent has been granted by the Indian Patent Office in March 2025. This patent relates to DNA Polymerase IIIC Inhibitors, including compositions-of-matter. This is the latest in the series of granted patents and pending patent applications that Acurx has filed to protect its proprietary technologies in the field of antimicrobials. To date, Acurx has obtained three U.S. patents, one Israeli patent, one Japanese patent, and now one Indian patent, in each case, which cover the ACX-375C program, relating to DNA Polymerase IIIC Inhibitors, with other country-level filings in process.
Robert J. DeLuccia, Executive Chairman of Acurx, stated: “Achieving this patent in India adds to our growing number of countries as we further develop our innovative, AI-supported drug discovery platform of second-generation DNA pol IIIC inhibitors”. He added: “While our lead DNA pol IIIC inhibitor is Phase 3-ready for oral treatment of C. difficile Infection, our second generation compounds in our program are systemically absorbed for potential oral and parenteral use in multiple clinical settings for treatment of infections caused by gram-positive bacteria, such as Staphylococcus aureus, including MRSA, VRE and DRSP, and B. anthracis or anthrax, a Bioterrorism Category A Threat-Level pathogen.”
